Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.53 |
| ▸ | GRK6 | P43250 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 14/20 | 0.48 |
| ▸ | JAK1 | P23458 | 8/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | FGR | P09769 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | SIK1 | P57059 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | STK10 | O94804 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434567 | 0.89 | JAK2 (0.50) | JAK2GRK6JAK3JAK1AURKA | |
| SCHEMBL1396179 | 0.89 | JAK2 (0.50) | JAK2GRK6JAK3JAK1AURKA | |
| SCHEMBL2160884 | 0.89 | JAK2 (0.50) | JAK2GRK6JAK3JAK1AURKA | |
| SCHEMBL2161741 | 0.89 | JAK2 (0.50) | JAK2GRK6JAK3JAK1AURKA | |
| SCHEMBL4434561 | 0.88 | JAK2 (0.49) | JAK2GRK6JAK3JAK1AURKA | |
| SCHEMBL2161166 | 0.88 | JAK2 (0.49) | JAK2GRK6JAK3JAK1AURKA | |
| SCHEMBL2161185 | 0.86 | GRK6 (0.48) | JAK2GRK6JAK3JAK1AURKA | |
| SCHEMBL1396078 | 0.86 | GRK6 (0.48) | JAK2GRK6JAK3JAK1AURKA | |
| SCHEMBL1396161 | 0.86 | JAK2 (0.70) | JAK2JAK3JAK1AURKANTRK1 | |
| SCHEMBL2161006 | 0.86 | JAK2 (0.70) | JAK2JAK3JAK1AURKANTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | THPO, MPL, MCL1 | JAK2 6/4885GRK6 4230/4885JAK3 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.